Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients

Chen, Jun; Jiang, Ruoxiang; Garces, Yolanda I.; Jatoi, Aminah; Stoddard, Shawn M.; Sun, Zhifu; Marks, Randolph S.; Liu, Yunpeng; Yang, Ping

doi:10.1016/j.lungcan.2009.04.006

Cited by 81 publications

(62 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of 2 studies in limited-stage small-cell lung cancer subjects were conflicting, although even in a study that failed to demonstrate statistically significant improvement on overall survival, subjects who quit smoking experienced a survival benefit. 10 This is very important in a detrimental disease such as small-cell lung cancer. The most important finding in the study involving early-stage non-small-cell lung cancer subjects 9 is the stronger beneficial effect of smoking cessation on overall survival and recurrence-free survival in light smokers compared with heavy smokers and in women.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review

Florou¹,

Gkiozos

Tsagouli

et al. 2014

Respir Care

View full text Add to dashboard Cite

BACKGROUND: Despite the established causal relationship between tobacco smoking and cancer, many cancer patients continue to smoke after diagnosis. This partly reflects ignorance of the beneficial effects of smoking cessation, even after diagnosis. The aim of this study was to demonstrate the effects of continuing or quitting smoking in patients with diagnosed cancer. METHODS: The study was based on a review of medical databases (PubMed Central, MEDLINE, Cochrane Library) in the last 30 y. All articles included in the present analysis were in English. RESULTS: In subjects with early-stage lung cancer, continued smoking after diagnosis is associated with an increased risk of all-cause mortality and decreased survival. Research has demonstrated significant differences in actuarial overall survival favoring the non-smoking group among subjects with lung cancer. In subjects with oral cancer, smoking cessation or reduction leads to a significant reduction in mortality. There is also evidence that tobacco smoking aggravates and prolongs radiotherapyinduced complications. Of particular importance is evidence that continued smoking is associated with adverse effects during anti-cancer treatment. Smoking promotes tumor progression and increases resistance to chemotherapy due to nicotine-induced resistance to apoptosis by modulating mitochondrial signaling. Continued smoking is also related to inferior outcomes of treatment with novel targeted therapies such as erlotinib. Smoking in subjects with gastric and lung cancer is also associated with an increased risk of developing second primary tumors. Quitting smoking after lung cancer diagnosis is associated with a better performance status, whereas persistent smokers have worse overall quality of life. Subjects who continue to smoke despite being diagnosed with cancer report more severe pain than subjects who have never smoked and greater pain-related functional impairment. CONCLUSIONS: Continued smoking after cancer diagnosis is related to reduced treatment efficacy and reduced survival, increased risk for second primary malignancies, and deterioration of quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review

Florou¹,

Gkiozos

Tsagouli

et al. 2014

Respir Care

View full text Add to dashboard Cite

show abstract

“…The effect of smoking may be mediated through inflammation, oxidative tissue damage, or immune suppression that acts on cancer progression [9,11]. Smoking-induced activated macrophages may generate reactive oxygen species that promote angiogenesis, tumor invasion, and metastasis [9,13]. Tobacco exposure also can alter multiple immunologic functions, including the innate and adaptive immune system [9].…”

Section: Discussionmentioning

confidence: 99%

“…The effect of smoking may be mediated through inflammation, oxidative tissue damage, or immune suppression that act on cancer progression [9,11]. Smoking-induced activated macrophages may generate reactive oxygen species that promote angiogenesis, tumor invasion, and metastasis [9,13]. Furthermore, smoking may increase blood carboxy-hemoglobin, producing relative hypoxia [13], and hypoxia-inducible factor has been shown to contribute to the RCC tumorigenesis process [16].…”

Section: Introductionmentioning

confidence: 99%

Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

et al. 2013

View full text Add to dashboard Cite

Describe the association between risk factors for renal cell carcinoma and the outcome of sunitinib treatment for metastatic disease.Explain the impact of active smoking on the outcome of sunitinib-treated metastatic renal cell carcinoma.Discuss obesity, hypertension, and diabetes in relation to the outcome of sunitinib-treated metastatic renal cell carcinoma. ABSTRACTBackground. Obesity, smoking, hypertension, and diabetes are risk factors for renal cell carcinoma development.Their presence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC).Methods. An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors.Results. Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with

show abstract

“…For SCLC cases, smoking percentages for men and women were 98.5% and 90.8%, respectively (10). Another study revealed that those smoking at the time of diagnosis and continuing to do so had a higher mortality (11). 93.8 % of the cases in our study were smokers.…”

Section: Discussionmentioning

confidence: 47%

Factors Affecting Survival in Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Objective: Small cell lung cancer (SCLC) constitutes about 15-25 % of lung cancers with high mortality rate. Herein we observed the effect of parameters at the time of diagnosis to survival of cases with SCLC. Methods: We evaluated 65 patients who were followed up in our oncology department retrospectively. Results: Tumor location and stage at the time of diagnosis, smoking history, accompanying comorbidities, ECOG PS, laboratory parameters and treatments applied in pursuit were evaluated. 3-month survival rate of patients was 75.9%, 50.2% for 6-month, 21.4% for 1 year, and 5.5% for 2 years during follow up. ECOG PS and stage were found statistically significant risk factors in model created to determine overall survival. Conclusion: Performance score at the time of diagnosis, stage and presence of liver metastasis are identified as prognostic factors for SCLC and of these factors are quite valuable to predict the clinical outcome.

show abstract

Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients

Cited by 81 publications

References 35 publications

Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review

Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review

Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Factors Affecting Survival in Small Cell Lung Cancer

Contact Info

Product

Resources

About